IGC Pharma (FRA:IGS1) Inventories, Finished Goods: €0.17 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:IGS1 IGC Pharma Inc FRA:IGS1
34 GF Score
Price €0.21
GF Value €0.20
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is IGC Pharma Inventories, Finished Goods?

IGC Pharma FRA:IGS1 -8.04% 34 Inventories, Finished Goods is €0.17 Mil as of Mar. 2026. GuruFocus rates FRA:IGS1 with a GF Score™ of 34/100 and a GF Value™ of €0.20 (Fairly Valued). The stock has 6 warning signs investors should review.

IGC Pharma's quarterly finished goods declined from Sep. 2025 (€0.18 Mil) to Dec. 2025 (€0.17 Mil) and declined from Dec. 2025 (€0.17 Mil) to Mar. 2026 (€0.17 Mil).

IGC Pharma's annual finished goods declined from Mar. 2023 (€0.50 Mil) to Mar. 2024 (€0.41 Mil) and declined from Mar. 2024 (€0.41 Mil) to Mar. 2025 (€0.24 Mil).

IGC Pharma Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for IGC Pharma's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IGC Pharma Inventories, Finished Goods Chart

IGC Pharma Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.83 0.65 0.50 0.41 0.24

IGC Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.24 0.18 0.17 0.17
FRA:IGS1
34GF Score
IGC Pharma Inc FRA:IGS1
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IGC Pharma Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of €0.17 Mil mean?
IGC Pharma (FRA:IGS1) has a Inventories, Finished Goods of €0.17 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on IGC Pharma and its competitors.
Is IGC Pharma's Inventories, Finished Goods too high?
IGC Pharma's current Inventories, Finished Goods is €0.17 Mil. Overall, IGC Pharma has a GF Score™ of 34/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does IGC Pharma's Inventories, Finished Goods compare to ATNM and ACTU?
IGC Pharma's Inventories, Finished Goods of €0.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on IGC Pharma and its competitors. IGC Pharma's current Inventories, Finished Goods is €0.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IGC Pharma stock overvalued right now?
Based on GuruFocus' analysis, IGC Pharma (FRA:IGS1) is currently considered Fairly Valued. The stock's GF Value™ is €0.20, compared to a current price of €0.21 — trading 3% above its estimated fair value. The current Inventories, Finished Goods is €0.17 Mil. IGC Pharma's overall GF Score™ is 34/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For IGC Pharma (FRA:IGS1), the current Inventories, Finished Goods is €0.17 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IGC Pharma (FRA:IGS1) Overvalued in 2026?

Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued. The current stock price of €0.21 is trading 3% above its estimated GF Value™ of €0.20. GuruFocus considers IGC Pharma to be Fairly Valued.

Key valuation signals for FRA:IGS1:

  • Inventories, Finished Goods: €0.17 Mil
  • GF Value™: €0.20 vs. price of €0.21 (3% above fair value)
  • GF Score™: 34/100 with 6 warning signs

No single metric tells the full story. See the FRA:IGS1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IGC Pharma Business Description

Other Exchanges IGC:USA
Address 10224 Falls Road, Potomac, MD, USA, 20854
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
34GF Score

Get the complete analysis for FRA:IGS1

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.21
Price
€0.20
GF Value